Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)

Overview

The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.

Full Title of Study: “Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 15, 2021

Arms, Groups and Cohorts

  • Clindamycin and Rifampicin
    • Patients treated with Clindamycin and Rifampicin
  • Clindamycin and Fluoroquinolone
    • Patients treated with Clindamycin and Fluoroquinolone

Clinical Trial Outcome Measures

Primary Measures

  • Failure of Clindamycine
    • Time Frame: within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)
    • New diagnosis of PJI at the same site, caused by the same microbial agent

Secondary Measures

  • Safety of Clindamycin
    • Time Frame: During the treatment and 6 month after
    • Safety of Clindamycin in the treatment of PJI
  • Correlation between failure of Clindamycin and blood level of Clindamycin
    • Time Frame: within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with PJI defined according to the IDSA. – Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin. – Infection may be acute or chronic, nosocomial or community-acquired. – Patient having received a curative treatment with Clindamycin. Exclusion Criteria:

  • Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic foot infections, spondylodiscitis, infections in external fixator, surgical site infections following neurosurgical management, bedsores, skin and soft tissue infections. – Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification. – Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype. – Patients having received suspensive treatment with Clindamycin. – Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days. – Patients refusing to participate – Patients under legal protection (guardianship, curatorship, ..)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Brest
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.